Search results
Results from the WOW.Com Content Network
Human embryonic kidney 293 cells, also often referred to as HEK 293, HEK-293, 293 cells, are an immortalised cell line derived from HEK cells isolated from a female fetus in the 1970s. [ 1 ] [ 2 ] The HEK 293 cell line has been widely used in research for decades due to its reliable and fast growth and propensity for transfection .
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy , effectiveness , and safety. As of November 2022 [update] , 40 vaccines are authorized by at least one national regulatory authority for public use: [ 1 ] [ 2 ]
[3] [11] Vaccination also cannot cause shedding of the COVID-19 virus since none of the COVID-19 vaccines authorized for use by the FDA or the World Health Organization as of December 2021 are live-virus vaccines. [12] [13] Despite this, a COVID-19 "vaccine shedding" conspiracy theory has subsequently emerged, leading to vaccine hesitancy among ...
Marty Verel, a 59-year-old kidney transplant recipient in Ohio, should have been near the top of the list to receive a COVID-19 vaccine. Yet like millions of others, he wasn’t having any luck ...
The updated COVID-19 vaccine is now available. Infectious disease doctors recommend being smart about the timing of your shot. You can expect similar side effects to the previous vaccines if you ...
The Janssen COVID‑19 vaccine, (Ad26.COV2.S) sold under the brand name Jcovden, [1] is a COVID‑19 vaccine that was developed by Janssen Vaccines in Leiden, Netherlands, [24] and its Belgian parent company Janssen Pharmaceuticals, [25] a subsidiary of American company Johnson & Johnson.
The new vaccines and boosters are monovalent (they target one strain of SARS-CoV-2, the virus that causes COVID-19) while the old vaccine targeted several strains, the FDA says.
A number of COVID‑19 vaccines began to become approved and available at scale in December 2020, with vaccinations beginning to ramp up at scale from the beginning of 2021, among them the Oxford–AstraZeneca COVID‑19 vaccine, based on an adenovirus vector and internally termed AZD1222. [citation needed]